A nanomedicine for targeted treatment of acute pancreatitis and its preparation method and application
Through hollow mesoporous Prussian blue nanoparticles loading BAPTA-AM and gabeester, combined with neutrophil membrane and DSPE-PEG-2N, targeted treatment of acute pancreatitis is achieved, solving the problems of calcium overload and trypsin activation. Improves therapeutic effect and drug delivery efficiency.
Patent Information
- Application Number
- CN202410017148.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-01-05
AI Technical Summary
The treatment of acute pancreatitis has cell damage caused by calcium overload and premature activation of trypsin, and traditional drug delivery efficiency is low and the half-life is short, making it difficult to achieve targeted therapy.
Using hollow mesoporous Prussian blue nanoparticles to load BAPTA-AM and gabeester, combining neutrophil membranes and DSPE-PEG-2N, release drugs in weak acid environments through targeting mechanisms, rapidly chelate calcium ions and inhibit trypsin Activity, blocking oxidative stress and inflammatory signaling cascades.
Accurate targeted treatment at the inflammatory site of the pancreas is achieved, cell protection effect is improved, drug accumulation time is prolonged, complication risk is reduced, and multiple protection mechanisms are provided.
Smart Images

Figure HDA0004651247830000011 
Figure HDA0004651247830000012 
Figure HDA0004651247830000013
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a nano drug for targeted treatment of acute pancreatitis and a preparation method and application thereof. Background Art
[0002] Acute pancreatitis is the most common gastrointestinal disease requiring emergency hospitalization, and the clinical mortality rate of severe acute pancreatitis is as high as 40%. The disease is usually caused by a variety of predisposing factors including gallstones, alcoholism, hypercalcemia, etc., which in turn triggers a series of reactions leading to autodigestion and death of pancreatic acinar cells and inflammatory cascades, ultimately causing serious and irreversible pancreatic function damage and even multi-organ complications. Its pathophysiological processes include intracellular calcium overload, premature activation of trypsin, oxidative stress injury, inflammatory cascades, etc. Among them, abnormal calcium ion signaling (overload) and premature activation of trypsin are the key upstream factors of acute pancreatitis. The disease has a sudden onset, complex pathophysiological processes, rapid progression of the disease and poor prognosis. There are also problems such as the deep anatomical location of the pancreas, low drug delivery efficiency caused by the blood-pancreatic barrier, and poor therapeutic effect. Based on the various problems above, although acute pancreatitis is a global disease burden, there is currently no effective drug to treat or prevent it.
[0003] Calcium overload mediates a series of cellular events such as intracellular induction of apoptotic signaling pathways and systemic proinflammatory responses, and the resulting cellular events further aggravate the elevated cellular calcium levels, resulting in mitochondrial dysfunction, impaired unfolded protein response, and impaired autophagy, ultimately leading to a vicious cycle of acinar cell death.
[0004] BAPTA-AM is a membrane-permeable calcium ion chelator. Due to the presence of ester bonds in its structure, it does not chelate calcium ions in the blood and is extremely safe. However, when it enters the cell, it is specifically hydrolyzed into BAPTA by esterase, which can efficiently and quickly chelate intracellular calcium ions, thereby exerting the ability to clear calcium overload at the pathological and physiological source of the disease. However, it is poorly soluble in water, cannot be administered intravenously, is ineffective when taken orally, and has poor organ selectivity in the body, which hinders its clinical transformation.
[0005] Premature activation and release of trypsin can cause mitochondrial dysfunction, cell necrosis, digestion of the pancreas and its surroundings, and result in massive death of acinar cells.
[0006] Gabexate is a class of non-peptide protease inhibitors that can inhibit the activation of trypsin and reduce pancreatic damage, but its half-life is extremely short (less than 10 minutes) and requires continuous and high-dose administration, making it difficult to achieve the optimal therapeutic effect.
[0007] Prussian blue nanomaterials (PB NPs) are inorganic materials with enzyme-mimicking capabilities, which can inhibit the release of inflammatory factors and have the ability to scavenge reactive oxygen species (ROS). At the same time, hollow mesoporous Prussian blue nanomaterials (HMPB NPs) can be obtained by hydrothermal etching, which have a higher specific surface area and stronger drug loading capacity. However, there are few studies on hollow mesoporous Prussian blue nanomaterials loaded with hydrophilic and hydrophobic drugs in oxidative stress-related diseases.
[0008] In addition, the deep anatomical location of the pancreas, the lack of precise targeting mechanisms for damaged pancreatic cells, and the existence of the blood-pancreatic barrier limit the effectiveness of traditional drug delivery to the core of pancreatic inflammatory tissue and specific functionally impaired acinar cell structures, resulting in reduced therapeutic efficacy and unexpected adverse reactions.
[0009] Neutrophils are the most aggressive immune cells that respond to inflammatory damage most quickly. They are usually the first white blood cells to be recruited. They camouflage drug-loaded nanoparticles by wrapping the neutrophil membrane and, under the guidance of chemokines, cross the blood-pancreatic barrier to be recruited to the lesion site.
[0010] DSPE-PEG is a PEGylated phospholipid with good biocompatibility and biodegradability. It can react with some chemical structures, peptides, etc. to form various types of compounds. It is often used as a carrier material for nanoformulations to assist drug release and improve the biocompatibility and stability of preparations. In addition, the phosphatidylethanolamine group in the DSPE-PEG structure is similar to the natural phospholipid molecular structure of the cell membrane, which enables it to embed some functional molecules (targeting structures, drug molecules, etc.) into the cell membrane. Summary of the invention
[0011] The purpose of the present invention is to provide a nano drug for targeted treatment of acute pancreatitis, which can quickly recruit targets at the damaged pancreatic site and release two drugs in a weakly acidic microenvironment, quickly chelate overloaded calcium ions at the lesion site, inhibit trypsin activity, and fundamentally and synergistically block the source of downstream oxidative stress and inflammatory signal cascades, further prevent pancreatic self-digestion, thereby effectively improving the redox state of the damaged cell microenvironment at the lesion site, saving dying cells, reducing the occurrence of complications, and improving survival rate, providing a comprehensive, synergistic, and multiple protection mechanism for the treatment of AP.
[0012] In order to achieve the above technical objectives, the present invention provides a nanomedicine for targeted treatment of acute pancreatitis, comprising inorganic nanoparticles, cell membranes, phospholipid derivatives and agents, wherein the inorganic nanoparticles are inorganic nanoparticles with loading capacity, the cell membranes are cell membranes that can cross the blood-pancreatic barrier and recruit lesion sites, the agents are agents comprising calcium ion chelators or blockers, trypsin inhibitors, anti-inflammatory agents, antioxidants or combinations thereof, and the phospholipid derivatives are compounds, polypeptides or antibodies with inflammation recruitment targeting or pancreatic acinar cell targeting.
[0013] Furthermore, the inorganic nanoparticles are selected from one of hollow mesoporous Prussian blue, hollow mesoporous manganese dioxide, hollow mesoporous cerium dioxide, mesoporous silica or hollow mesoporous polydopamine.
[0014] Furthermore, the cell membrane is selected from neutrophil membrane, macrophage membrane, mesenchymal stem cell membrane, erythrocyte membrane, platelet membrane or a mixed membrane thereof.
[0015] Furthermore, the medicament is a calcium ion chelator blocker and a trypsin inhibitor, the calcium ion chelator blocker is selected from BAPTA-AM, amlodipine, nifedipine, nimodipine or a combination thereof, and the trypsin inhibitor is selected from gabexate, ulinastatin, soybean Kunitz type trypsin inhibitor, soybean Bowman-Birk type trypsin inhibitor or a combination thereof.
[0016] Furthermore, the phospholipid derivative is DSPE-PEG-2N, and the DSPE-PEG-2N is a phospholipid derivative modified with propanediamine generated by phospholipid-polyethylene glycol-active ester (DSPE-PEG-NHS) and N,N-dimethyl-1,3-propanediamine.
[0017] Preferably, the inorganic nanoparticles are hollow mesoporous Prussian blue nanoparticles with a particle size of 50-300 nm and a polydispersity index (PDI) of 0.05-0.5, a mesoporous structure of 2-15 nm on the surface and a hollow cavity of 15-85 nm inside.
[0018] Preferably, the cell membrane is the cell membrane of neutrophils which respond most rapidly to inflammatory damage.
[0019] Preferably, the drug is the membrane permeable calcium ion chelator BAPTA-AM, and the trypsin inhibitor is gabexate.
[0020] The present invention provides a method for preparing the above-mentioned nanomedicine for targeted treatment of acute pancreatitis, comprising the following steps:
[0021] Step a. Preparation of hollow mesoporous Prussian blue nanoparticles. This process is divided into two steps. First, potassium ferrocyanide and polyvinyl pyrrolidone are put into hydrochloric acid (0.01-0.02M) for reaction for 20-25h to obtain mesogenic crystals. Then, the mesogenic crystals and polyvinyl pyrrolidone are put into hydrochloric acid (0.5-2M) for reaction for 2-4h to obtain nanoparticles.
[0022] Step b. drug loading, BAPTA-AM and gabexate: nanoparticles are placed in a mass ratio of 1:0.1-5 and stirred overnight for drug loading;
[0023] Step c. Cultivation and extraction of neutrophil membranes: First, the cell culture process requires induction, which is induced by 1.2%-1.4% dimethyl sulfoxide for 3-6 days, followed by extraction, which includes liquid nitrogen repeated freeze-thaw method, ultrasonic fragmentation method, hypotonic method or differential centrifugation method;
[0024] Step d. cell membrane wrapping, wrapping the cell membrane and the drug-loaded nanoparticles obtained in step b at a mass ratio of 1-6:1 (membrane protein mass: nanoparticle mass), including a water bath ultrasound method or an extrusion method;
[0025] Step e. Preparation of target head and insertion into the membrane: DSPE-PEG-NHS and 4-dimethylaminopyridine are dissolved in dimethyl sulfoxide, and N,N-dimethyl-1,3-propylenediamine is added after sufficient stirring. The mixture is stirred at room temperature for 24-48 hours. The solution is taken out and placed in a dialysis bag (3500Da-14000Da), and dialyzed with distilled water for 24-72 hours. The target head and nanoparticles are stirred at a mass ratio of 0.5-3:1 to obtain the final product.
[0026] The present application also includes the use of the above-mentioned nanomedicine in the treatment of acute pancreatitis.
[0027] The beneficial effects of the present invention are as follows: 1) in terms of nanocarriers, the hollow mesoporous Prussian blue prepared by the hydrothermal method has the ability to resist oxidation and inhibit inflammatory factors, and the surface mesopores and the internal hollowness give it a strong ability to load drugs, and can achieve drug release in a slightly acidic lesion environment; 2) the carrier construction type selected by the present invention for loading drugs with inorganic materials has little research in the mouse acute pancreatitis model; 3) the dual loading of drugs, namely gabexate and BAPTA-AM, achieves the treatment of acute pancreatitis by jointly inhibiting the upstream activation signal calcium overload (BAPTA-AM) and trypsin activity (gabexate), and solves the problems of difficulty in drug administration and short drug half-life by nanocarrier loading; 4) the cell membrane wrapping (surface specific protein integrin β2) and the target head (PEGylated phospholipid modified by propylene diamine) work together to achieve the recruitment and precise targeting of the lesion site, and by wrapping the neutrophil membrane and inserting DSPE-PEG-2N into the membrane, the drug-loaded nanoparticles reach the lesion site in a very short time to exert their effects. This solves the problem that the deep anatomical location of the pancreas, the lack of precise targeting mechanisms for damaged pancreatic cells, and the existence of the blood-pancreatic barrier limit the effectiveness of traditional approaches to deliver drugs to the core of pancreatic inflammatory tissue and the acinar cell structure with damaged specific functions, resulting in reduced therapeutic effects and unexpected adverse reactions. 5) The nanomedicine of the present invention actively recruits targeted lesions to avoid immune clearance, prevent drug leakage, and prolong the circulation time, thereby increasing the accumulation of drugs at the inflammatory site and maximizing the therapeutic effect. It combines the functions of BAPTA-AM in eliminating calcium overload and gabexate (Ga) in inhibiting trypsin activity at the lesion site, fundamentally blocking the source of downstream acinar cell apoptosis and necrosis events. In the complex and changeable pancreatic inflammatory environment of AP treatment, it can treat both the symptoms and the root causes, and achieve multi-target and multi-mechanism regulation. It provides a potential therapeutic strategy for the treatment of acute pancreatitis and inflammatory diseases, and has a high application prospect. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 (A) X-ray diffraction patterns of mPB (bottom) and HMPB (top), (B) X-ray photoelectron spectra of mPB (top) and HMPB (bottom), (C) high-resolution spectrum of iron element of HMPB, (D) UV spectra of mPB and HMPB (450-800nm);
[0029] Figure 2 (A) N of mPB (lower) and HMPB (upper) 2 Isotherm adsorption curve and pore size distribution, (B) electron microscopy of mPB (left) and HMPB (right) NPs;
[0030] Figure 3(A) 7-day stability of HMPB at 25°C (particle size distribution and PDI), (B) Changes in absorbance of HMPB under different pH conditions. (C) Antioxidant properties of HMPB NPs at different concentrations;
[0031] Figure 4 (A) Drug loading and encapsulation efficiency of BAPTA-AM and (B) gabexate, (C) UV spectra of HMPB, BAPTA-AM, gabexate, and HMPB@BA#Ga;
[0032] Figure 5 (A) Western Blot of HL-60 lysed cells, DMSO-induced HL-60 lysed cells and extracted cell membranes, (B) SDS-PAGE protein analysis, a. Marker b. Induced HL-60 cells c. Extracted neutrophil membranes d. Cell membrane-wrapped nanoparticles (M@HMPB);
[0033] Figure 6 DSPE-PEG-2N H NMR spectrum;
[0034] Figure 7 (A) Particle size diagram, (B) Potential diagram;
[0035] Figure 8 PBS stability of HMPB (B) and M@HMPB NPs (A);
[0036] Fig. 9 Assessment of NP recruitment in uninduced / induced endothelial cells;
[0037] Fig.10 Flow cytometry analysis of intracellular calcium levels in PACs damaged by TLCS induced by different treatments after incubation with Fluo-4 AM probe, n = 3;
[0038] Fig.11 Flow cytometric detection of ROS levels of different types of nanoformulations;
[0039] Fig.12 Fluorescence detection of mitochondrial membrane potential, scale bar: 100 μm, n = 6;
[0040] Fig.13 Flow cytometry detection of cell apoptosis of different types of nanoformulations;
[0041] Fig.14 Stimulation of macrophage polarization by TLCS-treated PACs cell culture medium and different formulations. Scale bar: 20 μm;
[0042] Fig.15Biodistribution of DiR fluorescently labeled free HMPB@DiR, M@HMPB@DiR, and 2N@M@HMPB@DiR in important organs (heart, liver, spleen, lung, kidney, and pancreas) in an acute pancreatitis mouse animal model after intravenous injection;
[0043] Fig.16 Pancreatic tissue cryosections Rhodamine B (red fluorescence: nanoparticles loaded with Rhodamine B in the pancreas), CD31 (green fluorescence: endothelial cells), DAPI (blue fluorescence: cell nuclei), (yellow is the overlapped part) immunofluorescence staining, scale bar: 100 μm; n = 6;
[0044] Fig.17 Immunofluorescence staining of pancreatic tissue cryosections with Rhodamine B (red fluorescence: nanoparticles loaded with Rhodamine B in the pancreas), amylase (green fluorescence: pancreatic acinar cells), and DAPI (blue fluorescence: cell nuclei) (yellow is the overlapped part), scale bar: 100 μm; n = 6;
[0045] Fig.18 Pancreatic tissue cryosections Rhodamine B (red fluorescence: nanoparticles loaded with Rhodamine B in the pancreas), CD68 (green fluorescence: macrophages), DAPI (blue fluorescence: cell nuclei), (yellow is the overlapped part) immunofluorescence staining, scale bar: 100 μm; n = 6;
[0046] Fig.19 Survival after different nanoparticle treatments in acute pancreatitis;
[0047] Fig. 20 Photos of the effects of pancreatic tissue treatment;
[0048] Fig.21 Hematoxylin-eosin (H&E) staining of pancreatic tissue;
[0049] Fig. 22 Serum indices (Panel A: amylase, Panel B: lipase), tissue homogenate indices (Panel C: trypsin), n = 8-12;
[0050] Fig.23 DHE fluorescence staining of pancreatic superoxide; scale bar: 200 μm (merge), 100 μm (enlarged); n = 6;
[0051] Fig.24Levels of malondialdehyde (MDA, Figure A), glutathione (GSH, Figure B), and superoxide dismutase (SOD, Figure C) in pancreatic tissue homogenate, n = 8-12;
[0052] Fig.25 Pancreatic TUNEL fluorescence staining; scale bar: 200 μm (Merge), 100 μm (Magnify); n = 6;
[0053] Fig.26 Immunofluorescence staining of ICAM-1 (green fluorescence: endothelial adhesion factor), CD31 (red fluorescence: endothelial cells), and DAPI (blue fluorescence: cell nuclei) in frozen sections of pancreatic tissue. Scale bar: 200 μm (Merge), 100 μm (Magnify); n = 6;
[0054] Fig. 27 MPO quantitative graph, n = 6;
[0055] Fig.28 Immunofluorescence staining of pancreatic tissue cryosections with F4 / 80 (green fluorescence: endothelial adhesion factor), CD31 (red fluorescence: endothelial cells), and DAPI (blue fluorescence: cell nuclei). Scale bar: 200 μm (Merge), 100 μm (Magnify); n = 6;
[0056] Fig.29 Western blot analysis of inflammatory factors in pancreatic tissue homogenate, nuclear factor kappa-B (NF-κB, Figure A), interleukin-6 (IL-6, Figure B) and tumor necrosis factor-α (TNF-α, Figure C) and semi-quantitative results n = 3;
[0057] Fig.30 Western blot analysis of pancreatic tissue homogenate related proteins, phosphorylation inositol-requiring enzyme 1, p-IRE-1 (Figure A), spliced X-box binding protein 1, sXBP-1 (Figure B), activating transcription factor 4 (ATF4, Figure C), C / EBP-homologous protein (CHOP, Figure D) and semi-quantitative results, n = 3;
[0058] Fig.31 Western blot analysis of pancreatic tissue homogenate-related proteins, Beclin-1 (Figure A), Sequestosome 1 (SQSTM1 / P62, Figure B), Microtubule-associated protein 1 light chain 3 (LC3, Figure C) and semi-quantitative results, n = 3;
[0059] Fig.32 Hematoxylin-eosin (H&E) staining of various organs - heart, liver, spleen, and kidney;
[0060] Fig.33 Alanine aminotransferase (ALT, Figure A), aspartate aminotransferase (AST, Figure B), serum creatinine level (Figure C), urea nitrogen level (Figure D);
[0061] Fig.34 Schematic diagram of the structure of DSPE-PEG-2N;
[0062] Fig.35 Synthesis steps of DSPE-PEG-2N;
[0063] Fig.36 Schematic diagram of the nanomedicine design of the present invention. DETAILED DESCRIPTION
[0064] 1. Material properties and functions
[0065] (1) Hollow Mesoporous Prussian Blue
[0066] Definition: Prussian Blue, also known as ferric ferrocyanide, has a chemical formula of Fe 4 [Fe(CN) 6 ] 3 , is a coordination compound with the structure (divalent iron ions are coordinated with 6 CN-, and then electrostatically bound to 4 trivalent iron ions). Its structure can be modified with multiple functions. Each Fe 2+ –CN–Fe 3+ There are five unpaired electrons in it.
[0067] Performance characteristics:
[0068] 1. It has a stable structure, adjustable size, controllable morphology, rich modification methods and excellent physical and chemical properties. It has excellent biosafety (approved by FDA), good magnetic properties (can be used as a contrast agent for magnetic resonance imaging, photoacoustic imaging and ultrasound imaging), PB can inhibit the release of inflammatory factors and has the ability to clear ROS.
[0069] 2. PB, as a material with a special structure in MOFs, is often selected as a drug carrier due to its porosity and large specific surface area, which gives the material a good drug loading rate. 3+ In PB, electrostatic interactions can be performed to increase drug loading rates, and modifications can be made to achieve targeted release. At the same time, as a drug carrier, the structural stability of PB is also much greater than that of other MOF materials, so drugs can be more effectively controlled and released.
[0070] (2) Neutrophil membrane
[0071] Circulating neutrophils are the immune cells that respond most rapidly to inflammatory damage and are usually the first leukocytes to be recruited. They adhere to active endothelial cells through membrane adhesion proteins and, during AP, further increase their migration across endothelial junctions under the guidance of chemokine gradients, thereby leaving the circulation system and selectively recruiting to damaged areas of pancreatic cells.
[0072] The neutrophil membrane was obtained by centrifugation after DMSO-induced differentiation of HL-60 (human promyelocytic leukemia cells). After induction, it specifically expressed integrin β2 protein (an important molecule that mediates neutrophil recruitment in inflammatory responses), which can specifically bind to ICAM-1 on endothelial cells in the lesion site, thereby enabling the nanoparticles to cross the blood-pancreatic barrier and be recruited in the lesion site.
[0073] (3) DSPE-PEG-2N
[0074] N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[ 123 I] iodobenzyl)-1,3-propylenediamine ( 123 I-labeled HIPDM) is a pancreatic imaging agent. The propylene diamine part (tertiary amine structure) on it is the reason for the pancreatic specific affinity. It can strongly bind to the injured acidic pancreatic acinar cells. It can be used as acinar cell-specific targeting ligand. DSPE-PEG-2N is co-incubated with membrane-encapsulated NPs and inserted into the membrane surface to achieve precise targeting of pancreatic acinar cells in the lesion site. The structure of DSPE-PEG-2N is shown in the figure Fig.34 As shown, the synthesis steps of DSPE-PEG-2N are as follows Fig.35 shown.
[0075] 2. Preparation method
[0076] a. Preparation of hollow mesoporous Prussian blue HMPB
[0077] 132mg potassium ferrocyanide (K 3 [Fe(CN) 6 ]) and 3g polyvinyl pyrrolidone (PVP) were added to 40mL 0.01M hydrochloric acid and stirred at room temperature for 30min. After stirring until a clear solution was obtained, the temperature was raised to 80°C and the reaction was continued for 21h. The solution was cooled to room temperature and centrifuged (12000-15000rpm / min), and washed several times with anhydrous ethanol and ultrapure water. After washing, the product mPB was lyophilized to obtain.
[0078] Weigh 20 mg of the product mPB and 100 mg of PVP, add them to 20 mL of 1 M hydrochloric acid, stir at room temperature until a uniformly dispersed blue solution is obtained, and place them in a reactor at 140 ° C for 2.5 h. After cooling, the above reaction product is washed several times (12000-15000 rpm / min), and freeze-dried to obtain the product hollow mesoporous Prussian blue (HMPB NPs).
[0079] b. Drug loading
[0080] 0.5 mg HMPB NPs, 0.5 mg BAPTA-AM and 2.5 mg Gabexate (Gabe) were added to 1 mL of dimethyl sulfoxide (DMSO) solution and stirred overnight. The drug-loaded hollow mesoporous Prussian blue (HMPB@BA#Ga) was obtained by centrifugation.
[0081] c. Cell membrane extraction
[0082] First, human promyelocytic leukemia cells (HL-60 cells) were induced to differentiate with 1.25% DMSO for 4-5 days. The differentiated cells were separated from the culture medium by centrifugation (1000 rpm, 5 min), and washed once with PBS buffer solution. Next, the separated cells were suspended in a pre-cooled hypotonic buffer (D-mannose, sucrose, bovine serum albumin, etc., pH = 7.4) containing protease inhibitors.
[0083] The cells were then frozen and thawed three times with liquid nitrogen (10 minutes each time) and ultrasonicated on ice four times.
[0084] Finally, the cell membrane is separated by centrifugation. First, the organelles are separated by low speed (2500-5000rpm / min), and then the supernatant is centrifuged by high speed to obtain the cell membrane (20000-25000rpm).
[0085] The cell membrane and drug-loaded nanoparticles (mass ratio of membrane protein:HMPB = 1:1) were ultrasonically blown in an ice water bath for 4-10 minutes to obtain cell membrane-wrapped nanoparticles (M@HMPB@BA#Ga).
[0086] d. Preparation of target head and insertion into membrane
[0087] DSPE-PEG-NHS (phospholipid-polyethylene glycol-active ester), purchased from Xi'an Ruixi Biotechnology Co., Ltd.) is a PEG active derivative, and the PEG backbone has good hydrophilicity and water solubility. The succinimidyl ester (NHS) at the other end reacts effectively with primary amine groups at pH 8-10. Therefore, through the reaction of NHS and amine, DSPE-PEG-NHS can be easily combined with liposomes and other nanoparticles.
[0088] 100 mg DSPE-PEG-NHS and 12.5 mg DMAP were dissolved in 20 mL dimethyl sulfoxide (DMSO), stirred thoroughly, and then 100 μL of N, N-dimethyl-1, 3-propylenediamine (350 mg / mL) was added and stirred at room temperature for 48 h. The solution was taken out and placed in a dialysis bag (molecular weight: 3500DA), dialyzed with distilled water for 72 h, and the solution was freeze-dried after dialysis to obtain DSPE-PEG-2N.
[0089] Take 200 μL DSPE-PEG-2N (1.25 mg / mL) and add it to 0.125 mg / mL M@HMPB@BA#Ga. After stirring for 30 minutes, centrifuge to obtain the final product 2N@M@HMPB@BA#Ga.
[0090] 3. Structure and performance characterization
[0091] 1. Preparation and structural identification of hollow mesoporous Prussian blue nanoparticles (HMPB NPs)
[0092] 1.1 Structural identification of mPB and HMPB:
[0093] Hollow mesoporous Prussian blue nanoparticles were synthesized by hydrothermal reaction under a certain acid concentration. Their hydration dynamic size was about 100 nm and their surface potential was about -20 mV. They were characterized by the following methods.
[0094] 1.1.1XRD, XPS, UV, FTIR
[0095] The structure of Prussian blue and the retention of its original structure during etching were verified through four characterization methods: XRD, XPS, UV, and FTIR.
[0096] 1.1.1.1 X-ray diffraction (XRD)
[0097] From the X-ray diffraction pattern ( Figure 1 A) shows that the mPB and HMPB nanoparticles are highly consistent with the standard face-centered cubic XRD card (PDF No. 73-0687), and they all have 8 diffraction peaks at 2θ = 17.5°, 24.7°, 35.5°, 39.7°, 43.5°, 51.2°, 54.3° and 57.5°, corresponding to (200), (220), (400), (420), (422), (440), (600) and (620) diffraction mirrors, respectively. The intensity and sharpness of the diffraction peaks indicate the high crystallinity of the samples.
[0098] 1.1.1.2 X-ray Photoelectron Spectroscopy (XPS)
[0099] Through XPS ( Figure 1 B and C) confirmed that mPB and HMPB are composed of four elements: iron, carbon, nitrogen, and oxygen. The narrow spectrum / high-resolution spectrum of iron shows four main peaks at 723.2, 721.2, 712.6, and 708.2 eV, respectively, from Fe2p 1 / 2 and Fe2p 3 / 2 The peaks at 712.6 and 721.2 eV are similar to those of Fe 3 [Fe 2 (CN) 6 ] 4 Fe 3+ Matching, the other peak (723.2, 708.2 eV) can be attributed to Fe 2+ .
[0100] 1.1.1.3 Ultraviolet spectrum UV and Fourier transform infrared spectrum FTIR
[0101] UV spectrum ( Figure 1 D) The characteristic peak of Prussian blue appears at around 718nm, and the waveforms at other peaks are highly overlapped. Fourier infrared spectrum at 2000cm -1 There are infrared characteristic peaks of cyano carbon-nitrogen triple bonds on the left and right.
[0102] In summary, XPS, XRD, infrared and ultraviolet jointly verified the synthesis of Prussian blue and the perfect retention of its crystal phase before and after etching.
[0103] 1.1.2 Specific surface area (BET)
[0104] Through the N 2 Analysis of adsorption-desorption isotherms ( Figure 2 A), the BET surface area of the nanoparticles ranged from 65.77 m 2 / g mPB increased significantly to 119.7m 2 / g HMPB, the total pore volume is from 0.2653cm 2 / g increased significantly to 0.7027m 2 / g. In addition, according to the BJH pore size analysis method, HMPB NPs generated mesopores of about 3.9nm and hollow structures of 25-40nm after acid etching. This indicates the successful preparation of hollow mesoporous structures, and also shows that HMPB has great potential in drug loading.
[0105] 1.1.3 Transmission electron microscopy (TEM)
[0106] Transmission electron microscopy of mPB and HMPB. Figure 2 B i is mPB, ii is HMPB)
[0107] 1.2 Performance analysis of HMPB NPs
[0108] 1.2.1 Stability
[0109] A certain concentration of mPB and HMPB NPs were weighed and uniformly dispersed in aqueous solution, and their particle size and dispersion index were tested for 7 consecutive days. They were stable at 25℃ and 4℃ and had good dispersion ( Figure 3 A is the 7-day stability of HMPB at 25°C).
[0110] 1.2.2 Responsiveness
[0111] A certain concentration of HMPB NPs was dispersed in PBS buffer solutions (10 mM) at pH = 7.4 and 6.5, and appropriate amounts of the solutions were taken at 1, 3, 6, 12, and 24 h, and their absorbance at 718 nm was detected using a UV spectrophotometer. Figure 3 B shows that compared with pH = 7.4, the absorbance of HMPB NPs in a weakly acidic environment of pH = 6.5 further decreases with time, so we have reason to speculate that the structure of HMPB NPs has undergone structural degradation under slightly acidic conditions, causing disordered aggregation of fragments and particles. This lays a solid foundation for the smooth release of loaded drugs.
[0112] 1.2.3 Antioxidant properties
[0113] HMPB NPs can effectively remove H 2 O 2 , OH and O 2· - and other free radicals to eliminate the oxidative stress caused by ROS, which plays a key role in the initiation and deterioration of acute pancreatitis. Figure 3As shown in C, after the introduction of HMPB NPs, the absorbance at 405-420 nm decreased. In addition, with the increase of HMPB NPs concentration, the absorbance at the characteristic peak further decreased.
[0114] 2. Preparation of HMPB@BA#Ga
[0115] 2.1 Drug loading and encapsulation efficiency
[0116] A certain concentration of BAPTA-AM and gabexate were added to HMPB NPs and stirred. After 24 hours, the supernatant was separated by centrifugation and the drug loading and encapsulation efficiency were evaluated by HPLC. Figure 4 A and B show that BAPTA-AM and gabexate can be efficiently encapsulated into HMPB NPs in a short time (24 h), with high encapsulation efficiency (EE%: 39.8% and 29.9%) and large drug loading capacity (LC%: 28.4% and 59.9%).
[0117] 2.2 Ultraviolet full spectrum
[0118] UV full spectrum scanning was performed on HMPB NPs, BAPTA-AM, gabexate and HMPB@BA#Ga loaded with drugs. Figure 4 C shows that the HMPB loaded with drugs has a protruding peak similar to the drug at around 250nm, which is located between the characteristic peaks of the two drugs, and the characteristic peak of Prussian blue itself still exists at 718nm. This strongly indicates the successful loading of the drug.
[0119] 3. Preparation of 2N@M@HMPB@BA@Ga
[0120] 3.1 Validation of neutrophil membrane extraction
[0121] After HL-60 cells were induced by a certain concentration of DMSO, they would express integrin β2-specific protein. After induction, the cells were subjected to hypotonicity, freeze-thaw, ultrasound, and centrifugation to obtain cell membranes, which successfully encapsulated the drug-loaded nanoparticles through ultrasound to generate M@HMPB@BA@Ga.
[0122] 3.1.1 Verification of integrin β2 expression
[0123] Uninduced HL-60 cells, DMSO-induced HL-60 cells, and extracted neutrophil membranes were characterized by Western blotting. Compared with uninduced HL-60 cells, the expression of integrin β2 protein was enhanced in induced cells. Moreover, during the extraction of cell membranes, this specific protein was still stable ( Figure 5 A).
[0124] 3.1.2 Successful encapsulation of nanoparticles by membrane
[0125] Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to compare the protein expression of induced cells, extracted cell membranes, and nanoparticles wrapped in cell membranes to determine the integrity of the proteins in the membrane. Figure 5 B shows that there are abundant neutrophil membrane proteins in the cell membrane-camouflaged NPs. These results indicate that the neutrophil membrane is coated on the core of HMPB NPs and the cell membrane proteins are successfully retained, thereby inheriting the biological properties of the source cells in the biomimetic nanomaterials.
[0126] 3.2 Preparation of DSPE-PEG-2N
[0127] DSPE-PEG-2N was obtained by reacting DSPE-PEG-NHS with N,N-dimethyl-1,3-propylenediamine under certain conditions. Figure 6 This is the H NMR spectrum of the product DSPE-PEG-2N. The obtained DSPE-PEG-2N was inserted into the cell membrane by stirring with the coated nanoparticles to obtain 2N@M@HMPB@BA#Ga.
[0128] 3.3 Characterization of 2N@M@HMPB@BA#Ga
[0129] 3.3.1 Particle size
[0130] Depend on Figure 7 A, HMPB NPs are nanoparticles with a particle size of about 101.3 nm, and the particle size increases slightly after loading the dual drugs. After wrapping the cell membrane, the irregular cubic hydrodynamic diameter of the membrane-coated NPs is slightly larger. After inserting DSPE-PEG-2N on the membrane surface, the final nanoparticle hydrodynamic size is about 134.7 nm.
[0131] 3.3.2 Potential diagram
[0132] Depend on Figure 7 B, The surface zeta potential of HMPB NPs is around -20 mV. When the surface is coated with cell membrane, its surface zeta potential is less than that of the core (-30.1 mV), but comparable to that of neutrophil membrane-derived vesicles, again indicating the consistency and integrity of the membrane coating.
[0133] 3.3.3 PBS stability
[0134] A certain concentration of HMPB NPs and M@HMPB NPs were dispersed in PBS buffer solution (Phosphate buffer saline). Figure 8It can be seen that NPs with neutrophil membrane coating do show higher stability in physiological environment, showing the maintenance of particle size and monodispersity ( Figure 8 A). In contrast, uncoated NPs exhibited an uneven size distribution and increased particle size in PBS ( Figure 8 B). This also confirms the integrity of the neutrophil membrane coating and the stability of its encapsulated nanoparticles.
[0135] 4. Effect Experiment
[0136] 1. Characterization of the therapeutic effects of nanoparticle drugs at the cellular level
[0137] 1.1 Cytotoxicity assay
[0138] The isolated primary acinar cells were inoculated and cultured for 6 h, and different concentrations of 2N@M@HMPB@BA#GaNPs and HMPB NPs with equivalent concentrations were added and co-cultured for 12 h (the concentrations written represent the concentrations of HMPB NPs in all preparations). The doses of HMPB NPs and membrane-encapsulated biomimetic HMPB NPs (ranging from 0 to 100 μg mL -1 ) in primary pancreatic acinar cells (PACs). Even at 100 μg mL -1 At high equivalent drug concentrations, cell viability still remained good and the survival rate exceeded 96%, indicating that the preparation has good cell compatibility.
[0139] 1.2 Nanoparticle hemolytic activity test
[0140] Nanoparticles of different types and concentrations were incubated with red blood cell solutions for 4 hours to observe their hemolysis. After treatment with different formulations (HMPB NPs, M@HMPB@BA#Ga NPs and 2N@M@HMPB@BA#Ga NPs), the transparent colorless supernatant in the red blood cell solution indicated negligible hemolysis. The hemolysis rates were all less than 2%, indicating that HMPB NPs, M@HMPB NPs and 2N@M@HMPB NPs met the safety standards for in vivo application in terms of hemolysis.
[0141] 1.3 Neutrophil membrane-coated nanoparticles achieve recruitment and uptake of HUEVC endothelial cells at the lesion site
[0142] In AP, neutrophils are known to participate in receptor-mediated adhesion to cytokine-activated endothelial cells. Here, neutrophil membrane-coated NPs were fluorescently labeled (rhodamine B) and added to normal or LPS-induced endothelial cells (HUVEC cells). When induced HUVEC cells were incubated with neutrophil-coated NPs, the fluorescence intensity increased significantly compared to normal cells (not induced by LPS), indicating that the biomimetic NPs have the ability to recruit inflammatory endothelial cells endowed by the neutrophil membrane coating ( Fig. 9 This binding may be attributed to the specific binding between integrin β2 on the neutrophil membrane and intercellular activation molecule 1 (ICAM-1) overexpressed on induced HUVEC cells.
[0143] 1.4 Calcium ion removal effect at the cellular level
[0144] Free cytoplasmic Ca in damaged pancreatic acinar cells 2+ The continuous increase in the number of inflammatory responses is the main initiating event and node of most acute pancreatitis. Fig.10 , taurocholate sodium (TLCS) induces Ca in isolated PACs 2+ Abnormal signaling (i.e., calcium overload), Ca 2 + The levels increased by 112-fold. Free BA drug could partially block TLCS-induced calcium overload (reduction of 28.0%), while free Gabe drug could not; HMPB@BA NPs and HMPB@Ga NPs treatment significantly enhanced the elimination of calcium levels compared with the model group, with a reduction of 50.0 and 30.9%, respectively. The improved therapeutic effects of BA and Gabe-loaded carriers may be partly attributed to the encapsulation of HMPB carriers, which effectively promoted the entry of free drugs into cells, leading to the elimination of calcium. Notably, BA#Ga co-loaded NPs (HMPB@BA#Ga NPs: 61.1% reduction) significantly reduced calcium content compared with the model group, indicating that BA#Ga co-loaded NPs have a strong inhibitory effect on calcium overload. Neutrophil-coated formulations (M@HMPB@BA#Ga NPs) reduced calcium levels by more than 80%, further enhancing calcium clearance, while 2N@M@HMPB@BA#Ga NPs treatment even surprisingly restored it to a level comparable to that of normal cells. The therapeutic effect of the two-drug co-treatment group may be attributed to the fact that they may inhibit the feedback loop of intracellular calcium overload and the cell damage cascade by combining calcium chelation and trypsin inhibition, with blocking the cell damage cascade of PACs as the core, thereby reducing intracellular Ca 2+ This combination, together with the neutrophil membrane coating, further enhances the synergistic calcium clearance effect by promoting cellular uptake, resulting in the restoration of calcium levels to near normal range within the assay period.
[0145] 1.5 ROS scavenging effect at the cellular level
[0146] After the initial intracellular calcium overload and production of trypsin, mitochondrial calcium uptake and output become dysfunctional, leading to excessive ROS production and changes in mitochondrial membrane permeability. Fig.11 As shown, drug-loaded NPs, including HMPB@Ga NPs and HMPB@BA NPs, exhibited significant ROS scavenging effects in damaged PACs (ROS decreased by 38.8% and 48.5%, respectively, compared with the model group). Blank HMPB NPs, which are generally considered to be an effective free radical scavenger, have been demonstrated by in vitro antioxidant experiments at pharmacological doses, further demonstrating their biological antioxidant activity, as they successfully reduced ROS levels in damaged PACs by approximately 9.1% after TLCS challenge. In addition to the possible enhancement of cellular uptake, the ROS scavenging effect of blank NPs further provides a theoretical basis for the significantly enhanced antioxidant activity of HMPB-loaded drugs over free drugs at the same dose. In addition, at the tested concentrations, M@HMPB@BA#Ga NPs and 2N@HMPB@BA#Ga NPs were better at scavenging ROS than other formulations, reducing ROS by 78.0% and 79.2%, respectively, compared with the model group, indicating a significant reversal of oxidative stress in damaged PACs.
[0147] 1.6 Restoration of mitochondrial function at the cellular level
[0148] Pancreatic mitochondria are highly susceptible to depolarization and loss of mitochondrial membrane potential (ΔΨm) induced by calcium overload (even at micromolar calcium ion levels). Consistent with the large increase in ROS generation after TLCS stimulation, we noted a significant decrease in ΔΨm in the model group (the JC-1 aggregate / monomer ratio decreased by 88.1% compared with normal PACs), indicating defective mitochondrial function after TLCS induction ( Fig.12 ). Although HMPB@Ga NPs were able to reduce the accumulation of ROS to some extent, they did not seem to further alleviate the collapse of ΔΨm. In contrast, HMPB@BA NPs effectively restored the mitochondrial membrane potential level, increasing JC-1 aggregates / monomers by 3.5 times compared with the model group, indicating effective inhibition of cell damage signal initiation. Considering the central role of cytoplasmic calcium overload in mitochondrial dysfunction, BA eliminates Ca 2+It seems to be more effective to exert pharmacological effects at the source of cell injury pathophysiology, thereby further inhibiting the downstream process of mitochondrial membrane polarization, thereby effectively restoring cell function. More strikingly, PACs exposed to M@HMPB@BA#Ga NPs showed significant improvement in the restoration of mitochondrial membrane integrity, with a 6.3-fold increase in ΔΨm compared with the model group. However, there was no statistical difference in the ΔΨm level between 2N@M@HMPB@BA#Ga NPs further doped with 2N and undoped NPs, suggesting that additional incorporation of 2N may not further improve the cellular level recovery of mitochondrial damage.
[0149] 1.7 Apoptosis analysis
[0150] The activation of cytopathic signals, such as intracellular calcium overload, premature activation of trypsin, oxidative stress, and inflammatory responses, will inevitably lead to acinar cell death, which is a hallmark of AP. Therefore, the protective potential of the prepared formula on damaged pancreatic acinar cells was further investigated. Fig.13 As shown, both HMPB@Ga and HMPB@BA restored cell viability and reduced apoptotic and necrotic cell populations after TLCS stimulation. In contrast, free BA and Gabe drug treatments partially protected PACs, while blank HMPB NPs had no measurable protective effect against apoptosis. When BA and Gabe co-loaded NPs were added to PACs, the percentages of both damaged cell proportions (apoptotic and necrotic: 19.7% and 0.64%) were significantly reduced, confirming that the two drug-loaded carriers were involved in the synergistic protection against cell death. Exposure to neutrophil-coated HMPB@BA#Ga formulations (with or without 2N modification) further resulted in a significant reduction in the proportions of apoptotic (10.63% and 13.77%, respectively) and necrotic (0.069% and 0.54%, respectively) PACs, indicating that the formulation has excellent efficacy in rescuing dying cells.
[0151] 1.8 Anti-inflammatory Properties
[0152] During AP, dead, dying, and injured pancreatic acinar cells often release substances from within the cells, including damage-associated molecular patterns (DAMPs), which trigger the recruitment of multiple immune cells (including neutrophils, monocytes, and macrophages) to the damaged area and initiate the activation of the inflammatory cascade. We further clarified whether the exogenous formulations were attributed to the anti-inflammatory effect. Macrophages were further stimulated with the culture medium of PACs cells treated with TLCS and different formulations to simulate the effects of substances released after acinar cell injury on subsequent inflammatory cells. When macrophages were exposed to the culture medium of stimulated PACs cells, the macrophages became polarized, their morphology changed, their cell state became irregular, and they produced multiple pseudopodia, which reflected the ability of macrophages to migrate and capture foreign substances ( Fig.14 ). We found that HMPB@BA NPs treatment significantly suppressed acinar cell injury and avoided macrophage differentiation, while HMPB@Ga NPs showed comparable efficacy to HMPB@BA NPs. Interestingly, when exposed to culture medium of injured acinar cells treated with prepared 2N@M@HMPB@BA#Ga NPs, the elongation of macrophage pseudopodia was abolished and migration was inhibited, resulting in the restoration of cell morphology very similar to that of normal cells, providing strong evidence for its potent anti-inflammatory properties.
[0153] 2. Characterization of the therapeutic effect of nanoparticle drugs in the animal model of acute pancreatitis induced by sodium taurocholate
[0154] 2.1 Construction of acute pancreatitis model
[0155] The pancreatic duct of mice fasted for 12 hours was retrogradely injected with 3.5% sodium taurocholate (TLCS) (100 μL / 100 g), and the duct was sutured after the injection. Blood was collected at 0, 6, 12, and 24 hours, and the heart, liver, spleen, lung, kidney, and pancreas tissues were collected at 24 hours for further testing.
[0156] 2.2 Biodistribution in vivo
[0157] The biodistribution of DiR-labeled HMPB@DiR, M@HMPB@DiR, and 2N@M@HMPB@DiR was quantitatively evaluated by intravenous injection in mice with acute pancreatitis. Compared with HMPB@DiR and M@HMPB@DiR, the pancreatic lesion sites showed obvious fluorescence signals in each time period. In addition, compared with the first two preparations, 2N@M@HMPB@DiR had a stronger fluorescence signal in the pancreas, and the recruitment speed and residence time were fast and long in each time period.
[0158] After the initial intravenous injection, most of the drug-loaded HMPB NPs (HMPB@DiR) accumulated in the liver and kidneys, but the fluorescence intensity was weak, and only a small amount of accumulation was observed in the pancreas ( Fig.15). Within the first hour after administration, the fluorescence intensity of the pancreas in the M@HMPB@DiR NPs group was significantly increased (2.56-fold) compared to the HMPB@DiR NPs group. The fluorescence intensity of the nanoformulations incorporated with 2N in the pancreas was significantly stronger, 1.73-fold higher than that of the cell membrane-encapsulated NPs at the same time point, which may be due to the further enhancement of the acinar cell targeting mediated by the functionalization of the 2N moiety. Over time, 2N@M@HMPB@DiRNPs accumulated in the pancreas at a faster rate and showed enhanced pancreatic retention at 3 and 6 hours, with fluorescence intensities 5.21 and 4.85 times higher than those of the HMPB NPs-treated groups. Twelve hours after administration, the fluorescence signal of pancreatic tissue in the HMPB@DiR NPs group was extremely weak; however, the groups treated with NPs coated with neutrophil membranes (M@HMPB@DiR NPs) and NPs with the additional addition of 2N targeting fragments (2N@M@HMPB@DiR NPs) still showed strong fluorescence in the pancreas.
[0159] This suggests that NPs encapsulating neutrophil membranes and 2N fragments are better enriched and retained in the pancreas, and improvements in this regard will enhance the effectiveness of AP-targeted therapy.
[0160] 2.3 Recruitment and targeting assessment at the tissue level
[0161] 2.3.1 Evaluation of the recruitment effect of neutrophil membrane-coated nanoparticles to lesion sites at the tissue level
[0162] Acute pancreatitis models were constructed by injecting HMPB@RhB, M@HMPB@RhB, and 2N@M@HMPB@RhB, respectively, and pancreatic tissues were obtained at specific times for frozen tissue section staining. Fig.16 As shown in the figure, within 1 hour after administration, the strong fluorescence distribution of the cell membrane-coated NPs (M@HMPB@RhB) was observed to overlap with the CD31-positive vascular endothelial cell area (green fluorescence signal), indicating that the NPs were quickly retained in the damaged pancreatic blood vessels in a short time. This may be because the neutrophil membrane-encapsulated drug delivery system simulates the process of circulating neutrophils being quickly captured on the endothelial surface and rolling along the blood vessels, and then adhering to the endothelium of the inflamed blood vessels through integrins. In addition, until 6h, M@HMPB@RhB NPs still had a high fluorescence signal and a high overlap with endothelial cells. However, 2N@M@HMPB@RhB NPs had a strong fluorescence signal at the endothelial cells at 1 hour, but the fluorescence signal decreased slightly at 6h. It is considered that under the action of 2N, the nanoparticles further moved and targeted.
[0163] 2.3.2 Evaluation of the effect of 2N targeting pancreatic acinar cells at the tissue level (pancreatic acinar cells-amylase)
[0164] Acute pancreatitis models were constructed, and HMPB@RhB, M@HMPB@RhB, and 2N@M@HMPB@RhB were injected respectively. Pancreatic tissue was taken at specific times for frozen tissue section staining. The strong RhB fluorescence distribution in the 2N@M@HMPB@RhB NPs-treated group overlapped with the amylase fluorescence-positive area and gradually increased over time ( Fig.17 ). It is speculated that the reason is that the 2N structure on the nanoparticles targets the weakly acidic pancreatic acinar cells in the lesion site of acute pancreatitis. Fig.16 The combination of endothelial cell signaling and migration once again demonstrated the adhesion and recruitment of 2N@M@HMPB@RhB in the first stage and the precise cell targeting in the second stage.
[0165] 2.3.3 Assessment of the ability to avoid immune cell internalization
[0166] It is worth noting that the immunofluorescence staining results of mouse pancreatic sections at various time points after injection showed that compared with uncoated HMPB NPs (HMPB@RhB), the overlap of membrane-coated HMPB NPs (M@HMPB@RhB / 2N@M@HMPB@RhB) in the CD68-positive macrophage area was almost negligible, which reflects that the cell membrane wrapping greatly avoids the specific internalization of nanoparticles mediated by macrophages in pancreatic inflammation ( Fig.18 ). In summary, through the results of 2.3.1, 2.3.2, and 2.3.3, neutrophil membrane encapsulation avoids adverse macrophage phagocytosis, promotes the arrest of NPs in the inflamed pancreatic vasculature, and migrates toward the injured area for further uptake by 2N-targeted acinar cells, resulting in relatively rapid, specific, and sustained localization of the nanoformulation in the pancreas, with effective therapeutic potential for the treatment of acute pancreatitis.
[0167] 2.4 Pancreatic tissue pathology recovery
[0168] First, the effect of nanoparticles on protecting pancreatic tissue damage was evaluated in a clinically relevant taurocholate sodium (TLCS)-induced AP mouse model. The types of nanoparticles are: 2N@M@HMPB, 2N@M@HMPB@BA, 2N@M@HMPB@Ga, 2N@M@HMPB@BA#Ga, and free Ga (free Gabexate).
[0169] 2.4.1 Survival rate
[0170] Survival rate is one of the most direct indicators for evaluating the severity of AP mice. In the model group, the mortality rate of AP model caused by TLCS injection was 41.6%, which is consistent with the mortality rate of clinical AP ( Fig.19Similarly, blank HMPB NPs did not improve survival, indicating that the protective effect of blank HMPB NPs was ineffective. Encouragingly, low-dose Gabe (0.75 mg / kg -1 )-loaded 2N@M@HMPB@Ga NPs increased the survival rate to 83.3%; however, the same dose of free Gabe drug (Gabe: 0.75 mg kg -1 ) did not significantly improve the survival rate of AP mice (survival rate was 66.6%). The results showed that the neutrophil-coated HMPB carrier can achieve a complete therapeutic effect with a reduced single drug dose, which may be due to its effective prevention of drug degradation and inactivation and improved targeting to the pancreas. A single injection of BA-loaded 2N@M@HMPB@BA (even at 200 μg kg -1 The survival rate of AP mice was significantly improved to 83.3% within 24 h even at low BA doses (only one injection of BA: 200 μg kg -1 and Ga 0.75 mg kg -1 ) can still achieve a 100% survival rate. The most intuitive life and death rate reflects the potential of 2N@M@HMPB@BA#Ga in the treatment of acute pancreatitis.
[0171] 2.4.2 Photos of the therapeutic effects of different nanoparticles on tissues, Fig. 20 shown.
[0172] 2.4.3 Hematoxylin-eosin (H&E) staining of pancreatic tissue Fig.21 shown.
[0173] Histopathological analysis showed that the interlobular spaces of pancreatic tissue in the mouse model of acute pancreatitis induced by sodium taurocholate were significantly enlarged (indicated by the arrows in the figure), acinar cells were significantly missing, necrotic and vacuolated (indicated by the dotted box in the figure), and inflammatory cell infiltration, tissue edema and hemorrhage were present in the lesion site (indicated by the triangles and circles in the figure). After treatment with free Ga, 2N@M@HMPB, 2N@M@HMPB@Ga, 2N@M@HMPB@BA, and 2N@M@HMPB@BA#Ga, the degree of damage to pancreatic tissue was alleviated to varying degrees. In particular, after treatment with 2N@M@HMPB@BA#Ga, some pancreatic tissue sections showed only slight histological damage, and acinar cell damage, inflammatory cell infiltration, edema, and hemorrhage were significantly reduced.
[0174] 2.4.4 Characteristic index detection (amylase, lipase, trypsin)
[0175] Serum amylase, lipase, and tissue trypsin levels were used as a basic evaluation of systemic efficacy, and their changes within 24 hours were studied. Compared with the normal group, serum amylase and lipase levels in AP mice after TLCS injury increased sharply by 5.3 times and 63.2 times, respectively, within the first 6 hours, and maintained this elevated level throughout the experiment, indicating that pancreatic damage was severe ( Fig. 22 , A: amylase, B: lipase, C: trypsin). Injection of a single dose of 2N@M@HMPB NPs only slightly reduced amylase and lipase levels by 30.4% and 30.9%, respectively, within the first 6 hours, but did not lead to a sustained statistical reduction in tissue pancreatic enzyme levels within 24 hours. The group injected with a single dose of 2N@M@HMPB@Ga NPs reduced serum amylase and lipase levels by approximately 42.3 and 43.2%, respectively, within the first 6 hours after injection. The low serum levels of these biomarkers were maintained throughout the treatment period. Administration of the same dose of free Ga partially attenuated amylase and lipase at 6 and 12 h, but the efficacy was much lower than that of intravenous injection of 2N@M@HMPB@Ga, and did not show any therapeutic effect at 24 h, probably due to its short half-life. Single-drug BA-encapsulated biomimetic 2N@M@HMPB@BA NPs (BA: 200 μg·kg -1 ) was much lower than that of the single-drug Gabe-encapsulated NPs group (Gabe: 0.75 mg kg -1 ), which was able to reduce tissue pancreatic enzymes with the same efficiency at 6h. And 2N@M@HMPB@BA NPs showed a more sustained therapeutic effect in the subsequent 24h, as shown by a more effective reduction in serum amylase and lipase compared with 2N@M@HMPB@Ga NPs, with a reduction of 28.9% and 41.9%, respectively, indicating a significant reduction in disease severity. It is worth noting that compared with the model group, a single dose of the BA#Ga co-loaded formulation significantly and rapidly reduced the levels of amylase and lipase in rats, with a decrease of 64.6% and 86.0%, respectively, in the first 6h, further verifying the synergistic therapeutic effect of BA and Gabe drug encapsulation. Surprisingly, trypsin levels continued to decrease throughout the treatment period and even returned to normal levels 24 hours after 2N@M@HMPB@BA#Ga treatment.
[0176] The activation of trypsin in pancreatic tissue is a key event in the pathogenesis of acute pancreatitis (AP), and its level continues to increase throughout the AP period. After 24 hours, the trypsin level increased significantly, which was 17.9 times that of the normal group. On the other hand, the trypsin level in the tissue of the HMPB blank NPs treatment group alone did not decrease, indicating that its antioxidant capacity could not inhibit the activation process of trypsin alone. Compared with the model group, the trypsin level in the pancreatic tissue homogenate of the 2N@M@HMPB@BA or 2N@M@HMPB@Ga NPs group was significantly reduced by 65.7% and 82.4%, respectively. The inhibitory effect of the Gabe and BA co-loaded formulation (2N@M@HMPB@BA#Ga NPs) treatment was significantly higher than that of the single drug formulation and reduced the trypsin activity to normal levels, further confirming that the prepared formulation has a considerable protective effect on the inflamed pancreas.
[0177] 2.5 Alleviating oxidative stress at the tissue level
[0178] Compared with the normal group, TLCS caused a sharp increase in pancreatic oxidative damage markers at 24 h, and the antioxidant function collapsed significantly. The levels of superoxide (DHE fluorescence intensity) and MDA increased by 7.68 times and 3.84 times, respectively ( Fig.23 and 24 A). In addition, GSH and SOD decreased by 76.4% and 58.3%, respectively, indicating that the enzyme antioxidant system was damaged under the action of inflammation ( Fig.24 B, 24C). Compared with the model group, 2N@M@HMPB@BA NPs significantly inhibited the oxidative stress damage in AP mice, as shown by the decrease in superoxide levels, the reduction in lipid peroxidation products, and the significant increase in antioxidant substances SOD and GSH, respectively, and the corresponding trends were more obvious than those in the 2N@M@HMPB@Ga NPs group. AP mice receiving the BA#Ga co-loaded formulation (2N@M@HMPB@BA#Ga) had a synergistic antioxidant effect compared with 2N@M@HMPB@BA NPs, while the reduction of ROS and MDA was more significant. In particular, after treatment with the BA#Ga co-loaded formulation, the superoxide level in mice was comparable to that of the normal group, indicating that ROS was significantly eliminated. This implies a strong ability to block ROS generation and scavenging lipid peroxidation processes and balance cellular redox homeostasis during AP.
[0179] 2.6 Inhibition of tissue cell apoptosis at the tissue level
[0180] Compared with the normal group, the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in pancreatic tissue after TLCS challenge was significantly increased (86.36 times) ( Fig.25). Treatment of AP mice with a single drug formulation (2N@M@HMPB@BA NPs or 2N@M@HMPB@Ga NPs) significantly reduced apoptotic cell levels by 33.4% and 59.7%, respectively, compared with the model group. Administration of an equal amount of free Ga did not result in any recovery of acinar cell apoptosis. In addition, the number of Tunel-positive cells in pancreatic tissues treated with 2N@M@HMPB@BA#GaNPs was significantly reduced (up to 74.8%), even to basal levels, indicating almost complete eradication of apoptotic cells.
[0181] 2.7 Inhibiting the inflammatory cascade and restoring the pancreatic tissue microenvironment at the tissue level
[0182] When the pancreas is damaged, the cellular contents released by partially necrotic and damaged cells activate monocytes and neutrophils, further propagating inflammation. The activation of these inflammatory cells promotes the secretion of inflammatory mediators, which in turn act as damage-associated molecular patterns (DAMPs) to aggravate ductal obstruction, activate proinflammatory signals and prematurely activate trypsinogen in acinar cells.
[0183] 2.7.1 Endothelial Adhesion Factor-ICAM-1
[0184] Depend on Fig.26 Immunofluorescence staining results showed that endothelial cell adhesion molecules (endothelial inflammatory marker ICAM-1) on the pancreatic endothelium (CD31-positive cells) were significantly activated at the beginning of the AP pathophysiological process. No obvious decrease in adhesion molecules was observed in the free Ga group and the blank HMPB NPs group, but a single injection of drug-loaded NPs (whether BA, Ga, or BA#Ga co-encapsulated) to AP mice led to a significant decrease in ICAM-1 expression around the endothelial area. This result may be attributed to the powerful acinar cell protective effect of the drug-loaded formulation. The formulation effectively reduced acinar damage, thereby preventing cell damage-mediated endothelial cell activation and subsequent microcirculatory damage.
[0185] 2.7.2 Neutrophil recruitment-MPO
[0186] The expression of neutrophil granzyme MPO in pancreatic tissue increased significantly, aggravating tissue inflammatory damage. Fig. 27 It can be seen that compared with the model group, 2N@M@HMPB@BA#Ga treatment reduced the MPO expression level of AP mice from 82.7 to 9.8 (MPO average intensity), which was significantly better than the free Ga group (55.2), blank HMPB NPs group (34.7), 2N@M@HMPB@BA NPs group (19.4) and 2N@M@HMPB@Ga NPs group (27.2). This result once again confirmed the anti-inflammatory regulatory effect of BA#Ga co-loaded NPs from the perspective of inhibiting neutrophil activation and granule content (MPO) release.
[0187] 2.7.3 Macrophage recruitment - F4 / 80
[0188] In the model group, strong expression of F4 / 80 was observed near endothelial cells presenting CD31 signals, indicating that a large number of monocyte-derived macrophages were significantly activated, recruited, and mainly distributed around and inside the endothelial surface of pancreatic capillaries and post-capillary veins ( Fig.28 ). The expression of F4 / 80 was significantly reduced in the group treated with neutrophil-coated formulations, indicating that these formulations further restricted the recruitment of macrophages in pancreatic tissue.
[0189] 2.7.4 Assessment of inflammation at the molecular level
[0190] The ability of neutrophil membrane-coated preparations to regulate the levels of inflammation-related molecules was further verified at the molecular level. Compared with the model group, both 2N@M@HMPB@Ga NPs and 2N@M@HMPB@BA NPs could effectively reduce the activation of the core inflammatory factor NF-κB and inhibit the nuclear translocation of NF-κB subunit p65, reducing it by 30.1% and 37.2%, respectively ( Fig.29 A). 2N@M@HMPB@BA#Ga NPs showed a remarkable ability to restore the nuclear distribution of NF-κB to normal levels, effectively inhibiting inflammation at the molecular level. In addition, a single administration of 2N@M@HMPB@BA#Ga NPs significantly reduced the levels of pro-inflammatory factors, including IL-6 and TNF-α ( Fig.29 B, C), and even had no statistical difference from the levels in the normal group.
[0191] 2.8 Therapeutic mechanism at the molecular level (inhibition of endoplasmic reticulum stress pathway and restoration of impaired autophagy in mice with experimental acute pancreatitis)
[0192] 2.8.1 Endoplasmic reticulum stress
[0193] In response to excess intracellular Ca 2+ , inositol requiring enzyme 1 (IRE1), which senses misfolded proteins in the lumen of the endoplasmic reticulum (ER), led to significant phosphorylation in the pancreas of AP mice (2.2-fold higher than that of the normal group) ( Fig.30 A). Further induction of spliced X-box binding protein 1 (sXBP1) was upregulated 1.8-fold compared to healthy mice ( Fig.30B). Compared with the model group, the 2N@M@HMPB@Ga NPs group inhibited IRE1 phosphorylation and sXBP1 expression, decreasing by 12.6% and 15.3%, respectively. These inhibitory effects were more pronounced in the 2N@M@HMPB@BANPs group, with p-IRE1 and sXBP1 reduced by 41.7% and 41.0%, respectively. BA#Ga co-loaded NPs largely prevented ER stress in AP, as evidenced by delayed induction and decreased protein expression of p-IRE1 and maintained the level of sXBP1, both of which were even reduced to levels comparable to those in the normal group.
[0194] In particular, BA#Ga co-loaded NPs (2N@M@HMPB@BA#Ga NPs) also inhibited the expression of ATF4 and downstream C / EBP homologous protein (CHOP) by 34.2% and 35.4%, respectively, which is another key signaling pathway for protein misfolding-mediated ER stress ( Fig.30 C and D).
[0195] Compared with the model group, 2N@M@HMPB@Ga NPs only slightly reduced the expression of ATF4 and CHOP by 19.8% and 18.6%, respectively, indicating that the inhibition of trypsin has a limited effect on alleviating ER stress. Therefore, it can be inferred that 2N@M@HMPB@Ga NPs can only intervene in the downstream cell damage mechanism mediated by trypsin activation.
[0196] 2.8.2 Impaired autophagy
[0197] Impaired autophagy is a prominent feature of AP, due to the reduced ability of lysosomes to degrade cellular cargo and the increased generation of autophagosomes. In particular, under severe ER stress, large amounts of Ca 2+ Released from the ER into the cytoplasm, it activates a large number of death-associated protein kinases and calcium-dependent protein kinases, thereby blocking the interaction between ER stress and autophagy, thereby inducing autophagy abnormalities. Given the strong inhibitory effect of 2N@M@HMPB@BA#Ga NPs on ER stress, we further determined its potential contribution to the recovery of impaired autophagy.
[0198] Indeed, in TLCS-induced AP, the levels of the autophagic vacuolar marker LC3-II and the autophagic substrate p62 / SQSTM1 were found to be elevated in acinar cells, consistent with the decreased autophagic flux during AP ( Fig.31A, B, C). The results showed that markers of impaired autophagy were consistently reduced in mice treated with 2N@M@HMPB@BA NPs (28.2% reduction in p62 / SQSTM1 and 27.6% reduction in LC3-II) or 2N@M@HMPB@Ga NPs (16.1% reduction in p62 / SQSTM1 and 18.2% reduction in LC3-II). Moreover, in the TLCS-induced AP model, BA and Gabe co-loaded NPs normalized autophagic flux, as shown by significantly reduced levels of LC3-II and p62 / SQSTM1, whose expression levels were even similar to those of normal pancreatic tissue.
[0199] 2.9 Biocompatibility assessment
[0200] Regarding the safety of nanoparticles, histological changes in major organs such as heart, liver, spleen, and kidney were observed after administration of different formulations during AP model treatment ( Fig.32 ). The results showed that no histological structural abnormalities were detected in any organs, thus confirming the safety of the formulation in vivo.
[0201] There was no significant difference in the blood biochemical analysis results reflecting liver damage (ALT alanine aminotransferase, AST aspartate aminotransferase) and kidney damage (Cre creatinine, BUN urea nitrogen) between the drug-treated group and the normal group. The serum biological indicators were all within the normal range, indicating that the drug-treated group did not cause damage to liver and kidney function ( Fig.33 ).
[0202] Taken together, these findings indicate that the prepared formulation has high biocompatibility and safety in vivo and does not produce significant adverse reactions during treatment, suggesting the potential of this formulation as a potential candidate drug for the treatment of AP.
[0203] Fig.36 A schematic diagram of the nanomedicine design of this embodiment is given.
Claims
1. A method for preparing a nanomedicine for targeted treatment of acute pancreatitis, characterized in that: The following steps are involved: Step a. Preparation of hollow mesoporous Prussian blue nanoparticles. This process is divided into two steps. First, potassium ferrocyanide and polyvinyl pyrrolidone are put into 0.01M-0.02M hydrochloric acid for reaction for 20-25h to obtain mesogenic crystals. Then, the mesogenic crystals and polyvinyl pyrrolidone are put into 0.5M-2M hydrochloric acid for reaction for 2-4h to obtain nanoparticles. Step b. drug loading, BAPTA-AM and gabexate: nanoparticles are placed in a mass ratio of 1:0.1-5 and stirred overnight for drug loading; Step c. Cultivation and extraction of neutrophil membranes: First, the cell culture process requires induction, which is induced by 1.2%-1.4% dimethyl sulfoxide for 3-6 days, followed by extraction, which includes liquid nitrogen repeated freeze-thaw method, ultrasonic fragmentation method, hypotonic method or differential centrifugation method; Step d. cell membrane wrapping, wrapping the cell membrane and the drug-loaded nanoparticles obtained in step b at a mass ratio of membrane protein mass: nanoparticle mass = 1-6:1, including a water bath ultrasound method or an extrusion method; Step e. Preparation of target head and insertion into the membrane: DSPE-PEG-NHS and 4-dimethylaminopyridine are dissolved in dimethyl sulfoxide, and N,N-dimethyl-1,3-propylenediamine is added after sufficient stirring. The mixture is stirred at room temperature for 24-48 hours. The solution is taken out and placed in a 3500Da-14000Da dialysis bag, and dialyzed with distilled water for 24-72 hours. The target head and nanoparticles are stirred at a mass ratio of 0.5-3:1 to obtain the final product.
